Medical technology company RaySearch Laboratories AB (RaySearch) (STO:RAYB) announced on Friday that Proton Therapy Center Czech (Prague PTC) has selected RayStation as its sole treatment planning system.
The company said this is its first order from Czechia.
This order has a total order value of SEK6,2m and the majority of the revenues will be recognised within the second quarter of 2019.
Prague PTC was established in 2012 and has since then been treating patients with a wide scale of cancer diagnoses such as prostate, lung, breast, head-and-neck and brain, using proton therapy.
RaySearch develops innovative software solutions to improve cancer care. The company markets the RayStation treatment planning system and RayCare, the next-generation oncology information system, worldwide.
(EUR1.00=SEK10.75)
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review